The Discounted Cash Flow (DCF) valuation of Halozyme Therapeutics Inc (HALO) is 77.46 USD. With the latest stock price at 52.02 USD, the upside of Halozyme Therapeutics Inc based on DCF is 48.9%.
Based on the latest price of 52.02 USD and our DCF valuation, Halozyme Therapeutics Inc (HALO) is a buy. buying HALO stocks now will result in a potential gain of 48.9%.
| Range | Selected | |
| WACC / Discount Rate | 7.1% - 9.3% | 8.2% |
| Long-term Growth Rate | 0.5% - 1.5% | 1.0% |
| Fair Price | 62.28 - 101.19 | 77.46 |
| Upside | 19.7% - 94.5% | 48.9% |